The Board has determined which competencies should be present at the
Board. The competence profile is reviewed annually by the Board.
A proposal for nomination of shareholder-elected Board members is
presented by the Nomination Committee to the Board taking into account
required competences as defined by the Board’s competence profile and
reflecting the result of the Board evaluation
process and the need for integration of new talent and diversity.
In nominating candidates, the Nomination Committee seeks to achieve a
balance between renewal and continuity, and it is Novo Nordisk’s
aspiration that a person is not nominated for election or re-election
if such Board member has been a Novo Nordisk Board member for 12 years
at the time of the general meeting.
To ensure that discussions include multiple perspectives
representing the complex, global pharmaceutical environment, the Board
aspires to be diverse in gender and nationality. On this background,
it is the aim that by 2020 the Board consists of at least two
shareholder elected Board members with Nordic nationality and at least
two shareholder elected Board members with another nationality than
Nordic - and at least three shareholder elected Board members of each
Executive search has helped identify Board members who meet the
Descriptions of the candidates' qualifications accompany the
agenda of the general meeting.